Okyo Pharma Ltd Stock Today
| OKYO Stock | USD 2.65 0.26 10.88% |
PerformanceSoft
| Odds Of DistressRisky
|
OKYO Pharma is selling at 2.65 as of the 28th of October 2025; that is 10.88% increase since the beginning of the trading day. The stock's open price was 2.39. OKYO Pharma has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 2nd of November 2024 and ending today, the 28th of October 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of May 2022 | Category Healthcare | Classification Health Care |
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom. The company has 37.61 M outstanding shares of which 23.55 K shares are now shorted by private and institutional investors with about 0.16 trading days to cover. More on OKYO Pharma Ltd
Moving against OKYO Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
OKYO Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Old Name | OKYO Pharma Ltd | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsOKYO Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand OKYO Pharma's financial leverage. It provides some insight into what part of OKYO Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
OKYO Pharma Ltd (OKYO) is traded on NASDAQ Exchange in USA and employs 4 people. OKYO Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 99.67 M. OKYO Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 37.61 M outstanding shares of which 23.55 K shares are now shorted by private and institutional investors with about 0.16 trading days to cover.
OKYO Pharma Ltd currently holds about 2.06 M in cash with (1.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.1.
Check OKYO Pharma Probability Of Bankruptcy
Ownership AllocationOKYO Pharma owns a total of 37.61 Million outstanding shares. OKYO Pharma has large amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check OKYO Ownership Details
OKYO Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Dauntless Investment Group, Llc | 2025-06-30 | 2.7 M | |
| Hpm Partners Llc | 2025-06-30 | 12.8 K | |
| Geode Capital Management, Llc | 2025-06-30 | 12.1 K | |
| Wealth Enhancement Advisory Services, Llc | 2025-06-30 | 10 K | |
| Ubs Group Ag | 2025-06-30 | 115 | |
| Renaissance Technologies Corp | 2025-06-30 | 0.0 | |
| Fny Investment Advisers, Llc | 2025-06-30 | 0.0 | |
| Continuum Advisory, Llc | 2025-06-30 | 0.0 | |
| Barclays Plc | 2025-03-31 | 0.0 | |
| Citadel Advisors Llc | 2025-06-30 | 0.0 |
OKYO Pharma Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. OKYO Pharma market risk premium is the additional return an investor will receive from holding OKYO Pharma long position in a well-diversified portfolio.
| Mean Deviation | 3.82 | |||
| Semi Deviation | 4.24 | |||
| Standard Deviation | 5.12 | |||
| Variance | 26.23 |
OKYO Stock Against Markets
OKYO Pharma Corporate Management
| Michael Beck | Founder | Profile | |
| Keeren Shah | Chief Officer | Profile | |
| PharmD Clementi | Chief Officer | Profile | |
| Rajkumar Patil | Chief Officer | Profile | |
| Gary Jacob | CEO Director | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OKYO Pharma Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in world development indicators. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OKYO Pharma. If investors know OKYO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OKYO Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of OKYO Pharma is measured differently than its book value, which is the value of OKYO that is recorded on the company's balance sheet. Investors also form their own opinion of OKYO Pharma's value that differs from its market value or its book value, called intrinsic value, which is OKYO Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OKYO Pharma's market value can be influenced by many factors that don't directly affect OKYO Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OKYO Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if OKYO Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OKYO Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.